CN113777330B - 一种疾病相关标志物的筛选方法、应用及试剂盒 - Google Patents
一种疾病相关标志物的筛选方法、应用及试剂盒 Download PDFInfo
- Publication number
- CN113777330B CN113777330B CN202111329614.0A CN202111329614A CN113777330B CN 113777330 B CN113777330 B CN 113777330B CN 202111329614 A CN202111329614 A CN 202111329614A CN 113777330 B CN113777330 B CN 113777330B
- Authority
- CN
- China
- Prior art keywords
- protein
- complex
- differential
- disease
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 42
- 201000010099 disease Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000012216 screening Methods 0.000 title abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 105
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 102
- 210000002966 serum Anatomy 0.000 claims abstract description 37
- 239000003550 marker Substances 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 16
- 238000001819 mass spectrum Methods 0.000 claims abstract description 15
- 238000004458 analytical method Methods 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 35
- 125000003147 glycosyl group Chemical group 0.000 claims description 21
- 238000010183 spectrum analysis Methods 0.000 claims description 8
- 108010084553 jacalin Proteins 0.000 claims description 7
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 5
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 5
- 102100039998 Apolipoprotein C-II Human genes 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 102100024783 Fibrinogen gamma chain Human genes 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 102100027833 14-3-3 protein sigma Human genes 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 102100031752 Fibrinogen alpha chain Human genes 0.000 claims description 3
- 102100037949 GTP-binding protein Di-Ras2 Human genes 0.000 claims description 3
- 101000723509 Homo sapiens 14-3-3 protein sigma Proteins 0.000 claims description 3
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims description 3
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 2
- 108010024284 Apolipoprotein C-II Proteins 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 101000951231 Homo sapiens GTP-binding protein Di-Ras2 Proteins 0.000 claims description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 2
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims description 2
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 101710125089 Bindin Proteins 0.000 claims 1
- 101710137044 Fibrinogen alpha chain Proteins 0.000 claims 1
- 229940019700 blood coagulation factors Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 108010048325 fibrinopeptides gamma Proteins 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 abstract description 26
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 abstract description 16
- 238000012163 sequencing technique Methods 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 30
- 208000025721 COVID-19 Diseases 0.000 description 29
- 206010000891 acute myocardial infarction Diseases 0.000 description 29
- 206010035664 Pneumonia Diseases 0.000 description 21
- 102000028555 IgG binding proteins Human genes 0.000 description 15
- 108091009325 IgG binding proteins Proteins 0.000 description 15
- 201000007983 brain glioma Diseases 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 101000783723 Homo sapiens Leucine-rich alpha-2-glycoprotein Proteins 0.000 description 12
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 102100032442 Protein S100-A8 Human genes 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- 101710156987 Protein S100-A8 Proteins 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 101710120037 Toxin CcdB Proteins 0.000 description 8
- 238000001261 affinity purification Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 108010028774 Complement C1 Proteins 0.000 description 3
- 101000839681 Homo sapiens Immunoglobulin heavy variable 4-30-2 Proteins 0.000 description 3
- 101001138132 Homo sapiens Immunoglobulin kappa variable 1-6 Proteins 0.000 description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 3
- 101000978132 Homo sapiens Immunoglobulin lambda variable 7-43 Proteins 0.000 description 3
- 102100028307 Immunoglobulin heavy variable 4-30-2 Human genes 0.000 description 3
- 102100020768 Immunoglobulin kappa variable 1-6 Human genes 0.000 description 3
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 3
- 102100023746 Immunoglobulin lambda variable 7-43 Human genes 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 2
- 108050008874 Annexin Proteins 0.000 description 2
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 2
- 102100031006 Beta-Ala-His dipeptidase Human genes 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 2
- 101150109687 CHMP4A gene Proteins 0.000 description 2
- 108010033547 Carbonic Anhydrase I Proteins 0.000 description 2
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 2
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 2
- 102100038275 Charged multivesicular body protein 4a Human genes 0.000 description 2
- 102100030149 Complement C1r subcomponent Human genes 0.000 description 2
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 102100032636 Copine-1 Human genes 0.000 description 2
- 102100032644 Copine-2 Human genes 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102100032323 Corticosteroid-binding globulin Human genes 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 102100024520 Ficolin-3 Human genes 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 2
- 101000919694 Homo sapiens Beta-Ala-His dipeptidase Proteins 0.000 description 2
- 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 description 2
- 101000910843 Homo sapiens Carboxypeptidase N catalytic chain Proteins 0.000 description 2
- 101000909153 Homo sapiens Carboxypeptidase N subunit 2 Proteins 0.000 description 2
- 101000941754 Homo sapiens Copine-1 Proteins 0.000 description 2
- 101000941777 Homo sapiens Copine-2 Proteins 0.000 description 2
- 101000868967 Homo sapiens Corticosteroid-binding globulin Proteins 0.000 description 2
- 101000761960 Homo sapiens Cytochrome P450 11B1, mitochondrial Proteins 0.000 description 2
- 101000761956 Homo sapiens Cytochrome P450 11B2, mitochondrial Proteins 0.000 description 2
- 101001052749 Homo sapiens Ficolin-3 Proteins 0.000 description 2
- 101001055314 Homo sapiens Immunoglobulin heavy constant alpha 2 Proteins 0.000 description 2
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 description 2
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 2
- 101000839686 Homo sapiens Immunoglobulin heavy variable 4-4 Proteins 0.000 description 2
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 description 2
- 101001047625 Homo sapiens Immunoglobulin kappa variable 2-40 Proteins 0.000 description 2
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 2
- -1 IgG compound Chemical class 0.000 description 2
- 102100026216 Immunoglobulin heavy constant alpha 2 Human genes 0.000 description 2
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 description 2
- 102100039352 Immunoglobulin heavy constant mu Human genes 0.000 description 2
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 2
- 102100028308 Immunoglobulin heavy variable 4-4 Human genes 0.000 description 2
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 description 2
- 102100022948 Immunoglobulin kappa variable 2-40 Human genes 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100036202 Serum amyloid P-component Human genes 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 101150063992 APOC2 gene Proteins 0.000 description 1
- 101710164022 ATP-dependent RNA helicase A Proteins 0.000 description 1
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
- 102100022460 Alpha-1-acid glycoprotein 2 Human genes 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100030942 Apolipoprotein A-II Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 102100037077 Complement C1q subcomponent subunit A Human genes 0.000 description 1
- 108010078044 Complement C1r Proteins 0.000 description 1
- 102100030152 Complement C1r subcomponent-like protein Human genes 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 description 1
- 102100031565 Cytidine and dCMP deaminase domain-containing protein 1 Human genes 0.000 description 1
- 102100034579 Desmoglein-1 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 102100031812 Fibulin-1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710117672 GTP-binding protein Di-Ras2 Proteins 0.000 description 1
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101000864670 Homo sapiens ATP-dependent RNA helicase A Proteins 0.000 description 1
- 101000678195 Homo sapiens Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
- 101000678191 Homo sapiens Alpha-1-acid glycoprotein 2 Proteins 0.000 description 1
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 description 1
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101000740726 Homo sapiens Complement C1q subcomponent subunit A Proteins 0.000 description 1
- 101000794279 Homo sapiens Complement C1r subcomponent Proteins 0.000 description 1
- 101000794267 Homo sapiens Complement C1r subcomponent-like protein Proteins 0.000 description 1
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 description 1
- 101000777693 Homo sapiens Cytidine and dCMP deaminase domain-containing protein 1 Proteins 0.000 description 1
- 101000924316 Homo sapiens Desmoglein-1 Proteins 0.000 description 1
- 101001065276 Homo sapiens Fibulin-1 Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101001037145 Homo sapiens Immunoglobulin heavy variable 2-5 Proteins 0.000 description 1
- 101000989005 Homo sapiens Immunoglobulin heavy variable 3-30-3 Proteins 0.000 description 1
- 101000839665 Homo sapiens Immunoglobulin heavy variable 3-43 Proteins 0.000 description 1
- 101000839683 Homo sapiens Immunoglobulin heavy variable 4-28 Proteins 0.000 description 1
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 description 1
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 description 1
- 101001138131 Homo sapiens Immunoglobulin kappa variable 1-8 Proteins 0.000 description 1
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 1
- 101001008315 Homo sapiens Immunoglobulin kappa variable 3D-20 Proteins 0.000 description 1
- 101001008253 Homo sapiens Immunoglobulin kappa variable 3D-7 Proteins 0.000 description 1
- 101000840270 Homo sapiens Immunoglobulin lambda constant 7 Proteins 0.000 description 1
- 101001005363 Homo sapiens Immunoglobulin lambda variable 3-16 Proteins 0.000 description 1
- 101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 1
- 101000609413 Homo sapiens Inter-alpha-trypsin inhibitor heavy chain H4 Proteins 0.000 description 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 1
- 101000839664 Homo sapiens Probable non-functional immunoglobulin heavy variable 3-38 Proteins 0.000 description 1
- 101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
- 101000956004 Homo sapiens Vitamin D-binding protein Proteins 0.000 description 1
- 101000818517 Homo sapiens Zinc-alpha-2-glycoprotein Proteins 0.000 description 1
- 102000028556 IgA binding proteins Human genes 0.000 description 1
- 108091009322 IgA binding proteins Proteins 0.000 description 1
- 102100026215 Immunoglobulin gamma-1 heavy chain Human genes 0.000 description 1
- 101710111858 Immunoglobulin gamma-1 heavy chain Proteins 0.000 description 1
- 102100040235 Immunoglobulin heavy variable 2-5 Human genes 0.000 description 1
- 102100029428 Immunoglobulin heavy variable 3-30-3 Human genes 0.000 description 1
- 102100028315 Immunoglobulin heavy variable 3-43 Human genes 0.000 description 1
- 102100028311 Immunoglobulin heavy variable 4-28 Human genes 0.000 description 1
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 description 1
- 101710196386 Immunoglobulin heavy variable 4-59 Proteins 0.000 description 1
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 description 1
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 description 1
- 102100020771 Immunoglobulin kappa variable 1-8 Human genes 0.000 description 1
- 102100027410 Immunoglobulin kappa variable 3D-15 Human genes 0.000 description 1
- 102100027403 Immunoglobulin kappa variable 3D-20 Human genes 0.000 description 1
- 102100027407 Immunoglobulin kappa variable 3D-7 Human genes 0.000 description 1
- 102100029614 Immunoglobulin lambda constant 7 Human genes 0.000 description 1
- 102100026911 Immunoglobulin lambda variable 1-40 Human genes 0.000 description 1
- 101710169441 Immunoglobulin lambda variable 1-40 Proteins 0.000 description 1
- 102100026921 Immunoglobulin lambda variable 1-44 Human genes 0.000 description 1
- 101710169443 Immunoglobulin lambda variable 1-44 Proteins 0.000 description 1
- 102100025936 Immunoglobulin lambda variable 3-16 Human genes 0.000 description 1
- 102100025874 Immunoglobulin lambda variable 3-27 Human genes 0.000 description 1
- 101710194383 Immunoglobulin lambda variable 3-27 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025515 Insulin-like growth factor-binding protein complex acid labile subunit Human genes 0.000 description 1
- 102100039457 Inter-alpha-trypsin inhibitor heavy chain H4 Human genes 0.000 description 1
- 102100023012 Kallistatin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100026553 Mannose-binding protein C Human genes 0.000 description 1
- 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
- WSSMMNVKLQZMEF-BEKOLJTOSA-N N-[(3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O WSSMMNVKLQZMEF-BEKOLJTOSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710202677 Non-specific lipid-transfer protein Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100022428 Phospholipid transfer protein Human genes 0.000 description 1
- 102100028318 Probable non-functional immunoglobulin heavy variable 3-38 Human genes 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 102100033469 Tubulointerstitial nephritis antigen-like Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100038611 Vitamin D-binding protein Human genes 0.000 description 1
- 102100021144 Zinc-alpha-2-glycoprotein Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种疾病相关标志物的筛选方法、应用及试剂盒。筛选方法包括:使用能够结合免疫球蛋白(Ig)的物质,分别从第一批健康样本血清和患病样本血清中纯化出Ig复合物;将与Ig相结合的蛋白进行蛋白质谱测序分析,比较健康样本与患病样本的差异,找到只出现在患病样本中的差异蛋白,即为该疾病相关潜在标志物。另外还可以通过以下步骤进一步验证该潜在标志物:使用第二批健康样本和患病样本的血清(扩大病例),纯化获得Ig复合物,利用差异蛋白的特异性抗体进行进一步鉴定。该方法先从血清中获得Ig复合物(而不是全血清),再将与Ig相结合的蛋白进行蛋白质谱测序联合特异性抗体分析,能够快速有效地筛选出疾病相关标志物。
Description
技术领域
本发明涉及分子生物学与免疫学技术领域,具体涉及一种疾病相关标志物的筛选方法、应用及试剂盒。
背景技术
生物标志物(Biomarker)是指一种具有可客观检测和评价的特性,可作为正常生物学过程、病理过程或治疗干预药理学反应的指示因子的生物体内物质。在疾病的诊断和治疗研究中,寻找和发现有价值的生物标志物已经成为当前医学领域的研究热点。
公开号CN108956791A的专利公开了一种大规模筛选蛋白质生物标志物的方法:将生物组织对照样本和参考样本(病理样本)匀浆、裂解;裂解液进行酶解、除盐等操作;用LC-MS/MS液质联用的方式进行蛋白质鉴定;通过比较质谱分析次数或质谱峰强度,分析样品蛋白的丰度变化,以MS1为基础,计算每个肽段的信号强度在LC-MS上的积分,以MS2的鉴定结果为定量基础,大规模对数据进行修正;通过修正的数据分析结果筛选出显著上调或下调的蛋白质生物标志物。
公开号CN111999403A的专利公开了一种瓦斯爆炸血清标志物筛选方法,以无创大鼠和瓦斯爆炸肺损伤大鼠血清样本进行LC-MS检测,采用LC-MS血清代谢组学技术进行分析,构建模型,利用模型进行数据处理,从候选代谢产物中筛选肺损伤模型生物标志物。
目前常用的筛选疾病相关特异性标志物的研究,普遍采用全基因组数据或者基因表达数据、全血清蛋白数据等作为分析基础。以新冠肺炎为例,目前通过蛋白质谱技术,已经揭示了重症COVID-19患者血清中蛋白质和代谢物的特征变化,鉴定了一些可能具有应用潜质的标志分子。然而,几乎所有寻找特异性生物标志物的研究都是利用 COVID-19的全血清蛋白[1,2,3]。对于蛋白质谱技术来说,由于其所用样品量少、而特异性标志物在血清或血浆含量却较低,显然,对于所需样本量少而为“优势”的蛋白质谱技术而言可谓是“大海捞针”,即要从这些目标分析物中筛选出有意义的标志物并非易事。
目前新型严重急性呼吸道综合征冠状病毒2型(severe acute respiratorysyndrome coronavirus 2,SARS-CoV-2)病毒感染诊断主要依赖核酸检测,尚缺乏血清学标志物,而且,其组织损伤程度也无可行的方法确定。因此积极研究SARS-CoV-2感染后的免疫应答反应对于寻找COVID-19生物标志物及鉴定组织损伤评估指标具有重要的临床意义。
参考文献:1.Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F,Sun R, Qian L et al: Proteomic and Metabolomic Characterization of COVID-19Patient Sera. Cell 2020, 182(1):59-72.e15.
2. Shu T, Ning W, Wu D, Xu J, Han Q, Huang M, Zou X, Yang Q, Yuan Y,Bie Y et al: Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19. Immunity 2020, 53(5):1108-1122.e1105.
3. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN,Peters-Clarke TM, Meyer JG, Quan Q, Muehlbauer LK, Trujillo EA et al: Large-Scale Multi-omic Analysis of COVID-19 Severity. Cell systems 2021, 12(1):23-40.e27.
发明内容
本发明的目的是针对现有技术中的上述问题,提供一种疾病相关潜在生物标志物的筛选方法、应用及试剂盒,该方法能够快速筛选出有意义的标志物,为疾病的诊断和治疗提供靶标基础。
第一方面,本发明提供了一种疾病相关潜在标志物的筛选方法,包括:
(1)使用能够结合Ig(免疫球蛋白)的物质,分别从第一批健康样本血清和患病样本血清中纯化出Ig复合物;
(2)对Ig复合物进行质谱分析和/或糖谱分析,比较健康样本与患病样本的分析结果,找到只高频出现在患病样本的Ig复合物中与Ig相结合的差异蛋白,和/或只高频出现在患病样本的Ig复合物中的差异糖基,该差异蛋白和/或差异糖基即为该疾病相关的潜在标志物。
上述筛选方法中,所述的健康样本,是指能够区别于患病样本的样本,例如,想要筛选某种疾病A相关的标志物,那么健康样本可以使用正常未患病人的样本,也可以使用患有其他疾病例如疾病B而未患疾病A的人的样本,只要能够与该疾病有明显区别,未被诊断为该疾病的样本即可。
可选或优选的,上述筛选方法中,还包括如下验证的步骤:
(3)进一步扩大健康样本和患病样本的数量,采用与步骤(1)相同的方法纯化获得Ig复合物,然后进行以下操作:
针对差异蛋白,利用该差异蛋白的特异性抗体,识别本步骤获得的Ig复合物中的差异蛋白,如果患病样品中该差异蛋白仍然高频出现或缺失,则进一步验证该差异蛋白为疾病相关的潜在标志物;
针对差异糖基,利用该糖基的结合物,或者糖谱分析,识别本步骤获得的Ig复合物的差异糖基,如果患病样本中该差异糖基仍然高频出现或缺失,则进一步验证该差异糖基为疾病相关的潜在标志物。
本步骤中使用的是新一批的健康样本和患病样本,数量可进一步扩大,大于第一批健康样本和患病样本,由于质谱或糖谱分析成本较高,第一批样本的数量只需要能够找到差异蛋白和/或差异糖基即可,当差异蛋白、糖基找到以后,再进一步大批量对这些差异蛋白、糖基的标志物特性进行验证,所得结果准确性更佳。
上述方法中,所述的高频,是指相较于其他样本,出现或缺失频率具有显著性差异,即丰度呈现显著性差异。
Ig,immunoglobulin,即免疫球蛋白。所述能够结合Ig的物质,与血清中的Ig结合后,可以分离纯化出Ig复合物,该复合物除含有Ig外,还包含了血清中存在的能够与Ig结合的其他蛋白类物质,部分蛋白可能存在糖基化修饰,因此利用能够结合Ig的物质将能够与Ig结合的蛋白进行了收集,再对这些蛋白进行蛋白质谱测序分析、糖谱分析,在分析结果中寻找其在健康样本和患病样本中的差异,就能够获得只高频在患病样本中出现的蛋白、糖基。最后利用免疫结合技术例如ELISA或Western blot或CBA流式等检测方法验证差异蛋白作为疾病相关标志物的可行性,对于差异糖基也可进一步针对性验证。
可选或优选的,上述方法中,所述能够结合Ig的物质,包括ProteinG、ProteinA、Jacalin、Hitrap、抗人IgD、抗人IgE中的至少一种。
可选或优选的,上述方法中,所述Ig复合物,包括IgG复合物、IgA复合物、IgM复合物、IgD复合物和IgE复合物中的至少一种。
第二方面,本发明提供了差异蛋白和/或差异糖基作为潜在标志物在制备疾病诊断或治疗药物中的应用,所述差异蛋白和/或差异糖基由以上任一所述方法筛选获得。
可选或优选的,上述应用中,所述疾病包括感染性疾病、免疫相关疾病、心血管疾病中的任何一种。
第三方面,本发明提供了一种检测试剂盒,用于辅助检测新冠肺炎,配合能够结合Ig的物质使用,所述试剂盒中包括抗CA1抗体、抗LRG1抗体、抗IgG-IgA复合物抗体中的至少一种。
第四方面,本发明提供了一种检测试剂盒,用于辅助检测脑胶质瘤,配合能够结合Ig的物质使用,其特征在于,所述试剂盒中包括抗S100-A8的抗体。S100-A8即后文中的Protein S100-A8。
与现有技术相比,本发明具有以下有益效果:
本发明的筛选方法首先基于亲和纯化技术利用能够结合Ig的物质,从样本血清中纯化出Ig复合物,再以Ig复合物中与Ig相结合的蛋白作为蛋白质谱测序技术的研究对象,通过测序分析不同的蛋白在健康样本和患病样本中的差异,进而寻找出只在患病样本血清中才出现的蛋白,或者对Ig复合物进行糖谱分析,找出差异糖基,即使这些成分在血清中的浓度非常低,通过本发明的方法也能够快速有效地筛选到,经过免疫技术对蛋白的鉴定、以及进一步对糖基的鉴定后,就能够验证其为疾病相关的标志物。
不管是外源性抗原(例如各种病毒、细菌及真菌),还是由各种疾病、外伤等导致细胞内抗原的释放,都可激活体内的免疫系统,其可通过特异性识别并结合抗原性物质清除抗原,达到免疫防御作用。例如,抗原性物质可激活B细胞产生特异性抗体,该抗体又通过与特定的抗原结合发挥免疫清除作用。因此,在疾病状态下,一些抗体所结合的抗原会带有疾病相关的分子特征,该分子可能是直接致病的病原微生物成分,也可能是组织损伤后内源性抗原成分,本发明通过先收集样本中的Ig复合物,再鉴定这些复合物中Ig所携带的抗原性物质,这些抗原性物质就是与Ig结合的蛋白,缩小了蛋白质谱技术的分析范围,更优于目前在全血清蛋白中寻找疾病相关标志分子的方案。另外我们发现,Ig复合物的糖谱分析结果中,健康样本和患病样本也存在显著差异,因此利用这些差异糖基也能够区分相关疾病。这种先形成Ig复合物,再基于Ig复合物寻找差异的方式,显著缩小了筛选范围,节省时间和资金成本,更具有可操作性。
本发明方法筛选出的新冠肺炎相关标志物CA1、LRG1、IgG-IgA复合物,能够特异性标识新冠肺炎,不仅可以作为新冠肺炎的生物标志物而且对于揭示疾病的发病机制,如新冠肺炎的免疫损伤机制也具有重要的意义,可能为相关的疾病治疗提供有效的靶点。
附图说明
图1为实施例1-鉴定血清中的Ig结合蛋白的流程及原理示意图。A为流程图,B为原理图。分别使用Jacalin、Protein G或抗人IgM亲和层析柱亲和纯化结合有IgA、IgG及IgM的Ig复合物,再进行Ig结合蛋白质谱鉴定以及数据分析。HC:健康组。CP(2 weeks):新冠肺炎恢复期2周。
图2为实施例1-Western blot法鉴定CA1及LRG1特异性呈现在新冠肺炎患者的Ig复合物中。A为不同组别的血清中IgA与CA1的结合水平。B为不同组别的血清中IgG与 LRG1的结合水平。Healthy control表示健康组,即正常人组,COVID-19 Convalescent Phase(2weeks)表示COVID-19恢复期2周,COVID-19 Vacciination表示COVID-19疫苗接种组,COVID-19 Convalescent Phase (6 months)表示COVID-19恢复期6个月。
图3为实施例1-Western blot法鉴定IgG-IgA复合物特异性呈现在新冠肺炎患者的Ig复合物中。A:鉴定在健康组、COVID-19恢复期2周、 COVID-19恢复期6个月以及COVID-19疫苗接种组的血清中IgA与IgG的结合水平。B:鉴定在健康组、COVID-19恢复期2周、COVID-19恢复期6个月以及COVID-19疫苗接种组的血清中IgG与IgA的结合水平。
图4为实施例2中冠心病患者与正常人的IgG结合蛋白质谱分析差异图,CH代表冠心病患者,NM代表正常人。
图5为实施例2中急性心肌梗死患者与正常人的IgG结合蛋白质谱分析差异图,AM代表急性心肌梗死患者,NM代表正常人。
图6为实施例2中急性心肌梗死与冠心病患者的IgG结合蛋白质谱分析差异图,AM代表急性心肌梗死患者,CH代表冠心病患者。
图7为实施例2中急性心肌梗死患者、冠心病患者与正常人三个人群的IgG结合蛋白质质谱分析差异图,AMI代表急性心肌梗死患者,CHD代表冠心病患者,NM代表正常人。
图8为实施例3中肺癌患者、脑胶质瘤患者、胃肠炎症患者、冠心病患者四组人群的IgG结合蛋白完成质谱分析后关于Protein S100-A8的表达差异对比图。
图9为实施例3中四组人群中的IgG结合蛋白完成质谱分析后关于Fibronectin的表达差异对比图。
图10为实施例3中四组人群中的IgG结合蛋白完成质谱分析后关于Suprabasin的表达差异对比图。
图11为实施例3中四组人群中的IgG结合蛋白完成质谱分析后关于Annexin A2的表达差异对比图。
图12为实施例3中四组人群中的IgG结合蛋白质谱结果分为癌症组和费癌症组后用T检验分析结果,显示5种蛋白在癌症组与非癌症组中的丰度差异显著。
图13为实施例3中四组人群中的IgG结合蛋白完成糖谱分析后显示的唾液酸(sialylation)修饰的糖蛋白的表达差异对比图。
图14为实施例3中四组人群中的IgG结合蛋白完成糖谱分析后关于G2FS修饰的糖蛋白的表达差异对比图。
图15为实施例3中四组人群中的IgG结合蛋白完成糖谱分析后关于G1S修饰的糖蛋白的表达差异对比图。
图16为实施例3中四组人群中的IgG结合蛋白完成糖谱分析后关于G1FS修饰的糖蛋白的表达差异对比图。
图17为实施例3中四组人群中的IgG结合蛋白完成糖谱分析后关于G2S修饰的糖蛋白的表达差异对比图。
图18为实施例3中对Protein S100-A8作为脑胶质瘤相关潜在标志物的免疫结合验证结果,显示其在脑胶质瘤组中出现更高频率的表达。
具体实施方式
下面结合较佳的具体实施例对本发明的技术方案进行详细解释和说明。
实施例1新冠肺炎相关潜在标志物的筛选
第一部分,纯化免疫球蛋白复合物及蛋白质谱分析。
分别取9例新冠肺炎患者(恢复期2周)及9例健康人血清200µL,用PBS稀释10倍,然后分别用Jacalin、Protein G、抗人IgM,通过亲和层析柱进行亲和纯化血清中的IgA复合物、IgG复合物及IgM复合物,这三种Ig复合物再用于蛋白质谱测序分析,操作流程如图1所示。
Jacalin能够亲和纯化出血清中的IgA,进而一起纯化出与IgA结合的各种蛋白。Protein G能够亲和纯化出血清中的IgG,进而一起纯化出与IgG结合的各种蛋白。抗人IgM能够亲和纯化出血清中的IgM,进而一起纯化出与IgM结合的各种蛋白。
经过进一步对蛋白质谱数据分析得到如下结果:
表1. IgA复合物中与IgA结合的蛋白
蛋白名称 | <i>P</i>值 | 新冠组/健康组 |
APOC2 | 0.04773551 | up |
IGLV3-16 | 0.04657575 | up |
CPB2 | 0.00073696 | up |
IGHV4-28 | 0.03035302 | up |
IGHV3-38 | 0.00227242 | up |
IGHV5-51 | 0.04680254 | up |
Ig heavy chain V-II region NEWM | 0.01933407 | up |
IGLC7 | 0.0212699 | up |
CFB | 0.00023813 | up |
CFP | 0.00800915 | up |
CHMP4A | 0.02580533 | up |
CDADC1 | 0.00021341 | up |
ITIH4 | 0.03186222 | up |
CNDP1 | 0.00137543 | up |
FCN3 | 0.00642634 | up |
CP | 0.00055504 | up |
F9 | 0.00158368 | up |
F10 | 0.0039227 | up |
*CA1 | 0.00198885 | up |
SERPINA3 | 5.44E-05 | up |
Ig lambda chain V-I region NEWM | 0.0284497 | up |
Ig lambda chain V-IV region Kern | 0.00927065 | up |
Ig heavy chain V-II region MCE | 0.00342457 | up |
APCS | 0.00103106 | up |
C1QA | 0.01148978 | up |
LRG1 | 0.00280689 | up |
ORM1 | 0.01297475 | up |
C2 | 0.00381825 | up |
C8A | 0.03259588 | up |
C8G | 0.01454743 | up |
*SERPINA6 | 0.00210371 | up |
CD14 | 0.04387445 | up |
C4B | 0.0393426 | up |
C6 | 0.01321296 | up |
CPN1 | 0.03042733 | up |
ORM2 | 0.02118024 | up |
CPN2 | 0.00733027 | up |
AZGP1 | 0.03598633 | up |
SERPINA4 | 0.01208177 | up |
IGFALS | 0.00916193 | up |
MASP1 | 0.00937332 | up |
C1RL | 0.00981707 | up |
FGG(C9JEU5) | 0.00505784 | down |
*只在新冠肺炎患者(恢复期2周)中出现的蛋白。
参见表1,新冠肺炎组相比于健康组,与 IgA 结合的 42 种蛋白质增加,1 种蛋白质减少,其中CA1及SERPINA6只在9例新冠肺炎患者中出现。
进一步对差异蛋白进行富集分析发现,与 IgA 结合的蛋白质在炎症、补体系统和凝血级联过程中高度丰富。
表2. IgG复合物中与IgG结合的蛋白
蛋白名称 | <i>P</i>值 | 新冠组/健康组 |
DMD | 0.04600074 | up |
CPB2 | 0.00086866 | up |
IGHV3-43 | 0.01853468 | up |
Ig heavy chain V-I region EU | 0.03803475 | up |
FBLN1 | 0.02433129 | up |
CFB | 0.00029404 | up |
CP | 0.00112882 | up |
F9 | 0.00350895 | up |
SERPINA3 | 0.00578391 | up |
Ig lambda chain V-I region VOR | 0.013433 | up |
*LRG1 | 9.36E-05 | up |
AMBP | 0.02206344 | up |
HPX | 0.00202254 | up |
Ig lambda chain V region 4A | 4.73E-05 | up |
ARG1 | 0.03769288 | up |
C2 | 2.71E-05 | up |
C8A | 0.0132836 | up |
C8G | 0.00085702 | up |
MBL2 | 0.03810486 | up |
CPN1 | 0.00021899 | up |
CPN2 | 0.0176004 | up |
MASP1 | 0.03555267 | up |
IGHV3OR15-7 | 0.02407551 | down |
APOC3 | 0.01131769 | down |
CHMP4A | 0.03738581 | down |
APOA2 | 0.01297376 | down |
LBP | 0.00194658 | down |
LGALS3BP | 0.00651023 | down |
*只在新冠肺炎患者(恢复期2周)中出现的蛋白。
通过表2可知,新冠肺炎组相比于健康组,与 IgG 结合的蛋白有 22 种蛋白质增加,6 种蛋白质减少,其中LRG1只在8例新冠患者出现,与 IgG 结合的蛋白质在补体激活、内吞作用和蛋白水解的负调节通路富集。
表3. IgM复合物中与IgM结合的蛋白
蛋白名称 | <i>P</i>值 | 新冠组/健康组 |
CFI | 0.0141665 | up |
APCS | 0.04476728 | up |
C2 | 8.74E-12 | up |
IGHV3-30-3 | 0.01111913 | up |
DSG1 | 0.01751852 | up |
CFHR4 | 0.00055017 | up |
APOC3 | 0.01959216 | down |
CNDP1 | 0.01094244 | down |
FCN3 | 0.02925569 | down |
LPA | 0.01584391 | down |
CD14 | 0.01512459 | down |
CETP | 0.03190065 | down |
PLTP | 0.00197844 | down |
参见表3,新冠肺炎组相比于健康组,与 IgM 结合的 6 种蛋白增加,7 种结合蛋白减少,但未发现只出现于新冠肺炎患者的蛋白。
第二部分,用Western blot方法进一步鉴定CA1及LRG1特异性呈现在新冠患者的免疫球蛋白复合物中。
针对第一部分中筛选出的候选标志物CA1及LRG1,对其进行鉴定。CA1,即碳酸酐酶I,Carbonic Anhydrase I。LRG1,亮氨酸丰富α2-糖蛋白1,leucine-rich-alpha-2-glycoprotein 1。
我们又进一步扩大样本数量,检测了20例健康人,25例COVID-19恢复期2周,20例COVID-19恢复期6个月以及4例COVID-19疫苗接种者的血清,用Jacalin亲和层析柱亲和纯化结合有IgA的免疫球蛋白复合物,所获免疫球蛋白复合物用抗CA1抗体以免疫印迹方法进行检测。用 Protein G亲和层析柱亲和纯化出IgG复合物,所获IgG复合物用抗LRG1抗体以免疫印迹方法进行检测。
检测结果参见图2A、B。结果发现,CA1及LRG1无例外地只发现在所有的COVID-19恢复期2周的患者血清所得免疫球蛋白复合物中,而在其他正常人(健康组)、疫苗接种者及康复后6个月COVID-19患者样本中未发现,表明CA1及LRG1可以作为新冠肺炎的潜在标志物。
另外,我们还鉴定了IgG-IgA复合物特异性呈现在新冠患者的免疫复合物,IgG-IgA复合物同时含有IgG和IgA两种免疫球蛋白。
在分析与IgA结合的免疫球蛋白复合物的蛋白谱时偶然发现,其中包含一定量的IgG,而健康人血清中与IgA结合的免疫球蛋白复合物中则缺少IgG。
为了证明新冠肺炎患者血清中与IgA结合的免疫球蛋白复合物中确实包含IgG(可能作为新标志分子),我们又进一步扩大样本,收集了15例健康人,20例新冠患者恢复期2周,15例COVID-19恢复期6月以及4例COVID-19疫苗接种者的血清,对Jacalin 亲和纯化的与IgA结合的免疫球蛋白复合物用抗人IgG进行Western blot分析。
结果发现,IgG无例外地只发现在所有的COVID-19恢复期2周的患者组中,而其他正常人组、疫苗接种者及康复后6个月COVID-19患者组中未发现,参见图3A。
同样,我们又用抗IgA抗体检测了亲和纯化的与IgG结合的免疫球蛋白复合物中是否存在IgA。
结果发现,IgA无例外地只发现在所有的COVID-19恢复期2周的患者组中,而其他正常人组、疫苗接种者组及康复后6个月COVID-19患者组中都未发现,参见图3B。说明IgG-IgA复合物特异性存在于新冠患者的免疫球蛋白复合物中,能够作为新冠肺炎的潜在标志物。
实施例2 冠心病(CHD)、急性心肌梗死(AMI)相关潜在标志物的筛选
第一部分:冠心病(CHD)相关潜在标志物的筛选
纯化IgG复合物及蛋白质谱分析:分别取冠心病(CHD)患者的血清,以及正常人(NM)的血清,用PBS稀释,然后用Protein G通过亲和层析柱进行亲和纯化血清中的IgG复合物。对与IgG结合的蛋白质进行质谱分析。
蛋白质谱分析结果参见图4,图中不同蛋白质标记所代表的蛋白名称如下表所示:
编号 | 基因 | 英文全称 | 中文全称 |
P02679 | FGG | Fibrinogen gamma chain | 纤维蛋白原γ链 |
P02671 | FGA | Fibrinogen alpha chain | 纤维蛋白原α链 |
P08493 | MGP | Matrix Gla protein | 细胞外基质Gla蛋白 |
P01023 | A2M | Alpha-2-macroglobulin | α-2巨球蛋白 |
P02774 | GC | Vitamin D-binding protein | 维生素D结合蛋白 |
P03951 | F11 | Coagulation factor XI | 凝血因子11 |
P02655 | APOC2 | Apolipoprotein C-II | 载脂蛋白C-II |
P02765 | AHSG | Alpha-2-HS-glycoprotein | α-2-HS糖蛋白 |
P02656 | APOC3 | Apolipoprotein C-III | 载脂蛋白C-III |
Q96HU8 | DIRAS2 | GTP-binding protein Di-Ras2 | GTP结合蛋白 Di-Ras2 |
P31947 | SFN | 14-3-3 protein sigma | 14-3-3sigma |
结果显示,与正常人相比,纤维蛋白原、细胞外基质Gla蛋白、α-2巨球蛋白、维生素D结合蛋白、凝血因子11、载脂蛋白C-II、 α-2-HS糖蛋白、载脂蛋白C-III、 GTP结合蛋白Di-Ras2及14-3-3sigma都高水平呈现在CHD患者血清中。表明上述蛋白可作为CHD相关的潜在标志物。
第二部分:急性心肌梗死(AMI)相关潜在标志物的筛选
纯化Ig复合物及蛋白质谱分析:分别取急性心肌梗死(AMI)患者的血清,以及正常人(NM)的血清,用PBS稀释,再用ProteinG从急性心肌梗死(AMI)及正常人(NM)血清中纯化获得IgG免疫复合物,对与IgG结合的蛋白进行质谱分析,寻找差异。
分析结果参见图5,图中不同蛋白质标记所代表的蛋白名称如下表所示:
编号 | 基因 | 英文全称 | 中文全称 |
P02679 | FGG | Fibrinogen gamma chain | 纤维蛋白原γ链 |
A0A087WSY4 | IGHV4-30-2 | Immunoglobulin heavy variable 4-30-2 | Ig重链可变区IGHV4-30-2 |
A0A075B6R2 | IGHV4-4 | Immunoglobulin heavy variable 4-4 | IGHV4-4 |
P02656 | APOC3 | Apolipoprotein C-III | 载脂蛋白C-III |
Q08211 | DHX9 | ATP-dependent RNA helicase A | ATP依赖性RNA解旋酶A |
P00742 | F10 | Coagulation factor X | 凝血因子10 |
A0A0C4DH72 | IGKV1-6 | Immunoglobulin kappa variable 1-6 | Ig轻链可变区IGKV1-6 |
P02671 | FGA | Fibrinogen alpha chain | 纤维蛋白原α链 |
P01619 | IGKV3-20 | Immunoglobulin kappa variable 3-20 | Ig轻链可变区IGKV3-20 |
结果显示,与正常人相比,纤维蛋白原、IGHV4-30-2、IGHV4-4、载脂蛋白C-III、ATP依赖性RNA解旋酶A、凝血因子10、IGKV1-6及IGKV3-20高水平呈现在AMI患者血清中。表明上述蛋白可作为AMI相关的潜在标志物。
冠心病(coronary heart disease,CHD)由冠状动脉血管发生动脉粥样硬化病变引起的心肌缺血所导致,如果冠心病不能得到有效治疗而任其发展,就有可能出现部分心肌急性坏死,转化成急性心肌梗死(acute myocardial infarction,AMI)。因此,为了更进一步寻找CHD和AMI之间的差别,准确判断患者病程发展,我们又将CHD和AMI患者中与IgG结合的蛋白进行了质谱分析比较。
第三部分:对CHD和AMI相关潜在标志物的进一步筛选
纯化Ig复合物及蛋白质谱分析:分别取冠心病(CHD)患者、极性心肌梗死(AMI)患者的血清,用PBS稀释,然后用Protein G通过亲和层析柱进行亲和纯化获得血清中的IgG复合物。对复合物中与IgG结合的蛋白质进行质谱分析。
蛋白质谱分析结果参见图6,图中不同蛋白质标记所代表的蛋白名称如下表所示:
编号 | 基因 | 英文全称 | 中文全称 |
P09871 | C1S | Complement C1s subcomponent | 补体C1S |
P01602 | IGKV1-5 | Immunoglobulin kappa variable 1-5 | IGKV1-5 |
P00736 | C1R | Complement C1r subcomponent | 补体C1R |
P00742 | F10 | Coagulation factor X | 凝血因子10 |
A0A0C4DH73 | IGKV1-12 | Immunoglobulin kappa variable 1-12 | IGKV1-12 |
A0A0C4DH67 | IGKV1-8 | Immunoglobulin kappa variable 1-8 | IGKV1-8 |
P01742 | IGHV1-69 | Immunoglobulin heavy variable 1-69 | IGKV1-69 |
A0A0C4DH55 | IGKV3D-7 | Immunoglobulin kappa variable 3D-7 | IGKV3D-7 |
A0A0C4DH25 | IGKV3D-20 | Immunoglobulin kappa variable 3D-20 | IGKV3D-20 |
P0DOX5 | Immunoglobulin gamma-1 heavy chain | 免疫球蛋白γ-1重链 | |
A0A087WSY6 | IGKV3D-15 | Immunoglobulin kappa variable 3D-15 | IGKV3D-15 |
结果显示,与CHD相比,AMI患者高水平呈现补体C1S、C1R、凝血因子10及IGKV1-5。而结合第一部分和第二部分的结果,与正常人IgG复合物蛋白质谱相比,AMI及CHD都突出呈现纤维蛋白原及载脂蛋白C-III。表明纤维蛋白原和载脂蛋白C-III能够作为CHD和AMI的潜在标志物,再结合第一部分和第二部分所筛选出的CHD和AMI各自的潜在标志物,就能够准确判断患者具体所患疾病,以及其病程进度如何。
图7显示了急性心肌梗死(AMI)、冠心病(CHD)和正常人(NM)这三群人中与IgG结合的蛋白质质谱分析结果,显示三群人蛋白谱的差异。
实施例3 脑胶质瘤相关标志物的筛选
纯化Ig复合物及蛋白质谱分析:脑胶质瘤患者、冠心病患者、肺癌患者、胃肠癌症疾病患者的血清共四组,每组10人,分别取血清用PBS稀释,然后用Protein G通过亲和层析柱进行亲和纯化血清中的IgG复合物。对所得IgG复合物中的蛋白质进行质谱分析以及糖谱分析。
参见图8和图9,质谱分析结果显示,相较于其他组,Protein S100-A8(5/10)和Fibronectin(纤黏连蛋白)(3/10)两种蛋白在脑胶质瘤患者血样纯化的IgG复合物中高水平表达。参见图10和图11,肺癌患者血清尤其高频率出现Suprabasin(5/10,即10例样本中5例显示高表达)和Annexin A2(膜联蛋白 A2)(4/10)。
用T检验分析发现,参见图12,当“t-test Difference”大于1.5或者小于-1.5,则该蛋白在两组中的丰度具有显著的差异性。软件分析出差异蛋白有五种:1.C4b-bindingProtein alpha chain(C4b结合蛋白α链)、,2.Ig alpha-2 chain C region(Igα-2链C区),3.Ig kappa chain V-II FR(Igκ链V-II FR),4.Ig mu heavy chain disease protein(Ig-μ重链病蛋白),5.Ig lambda chain V region 4A(Igλ链V区域4A)。
其中,癌症组(脑胶质瘤、肺癌、胃肠癌)与非癌症组(冠心病)相比,蛋白质谱显示Ig lambda chain V region 4A在癌症组水平远高于非癌症组,而C4b-binding Proteinalpha chainIg alpha-2 chain C region、Ig kappa chain V-II FR和Ig mu heavychain disease protein在非癌症组明显高于癌症组。这表明上述五种蛋白可作为癌症相关潜在标志物,其表达水平相对于非癌症对照样本显著升高或者降低即提示患癌可能性。
参见图13,糖谱分析结果显示,唾液酸(sialylation)在脑胶质瘤患者中也呈现高水平。另外,参见图14和图15,G2FS以及G1S在脑胶质瘤患者中也呈现高水平。参见图16,G1FS在肺癌患者中呈现高水平,参见图17,G2S在肺癌患者中呈现高水平。各图中,糖基结构中正方形表示N-acetylglucosamine(N-乙酰葡糖胺),浅灰色圆形表示galactose(半乳糖),深灰色圆形表示mannose(甘露糖),菱形表示sialic acid(唾液酸 ),三角形表示fucose(岩藻糖)。
经过上述质谱分析和糖谱分析,可以将Protein S100-A8、Fibronectin、唾液酸、G2FS、G1S作为脑胶质瘤相关的潜在标志物,而G1FS、G2S作为肺癌相关的潜在标志物。
当对唾液酸进行验证时,可以用西洋接骨木凝集素(SNA)或朝鲜槐凝集素(MAL)检测,其它的糖基可以用糖谱分析检测。
对于Protein S100-A8,我们还做了进一步的验证实验。
扩大样本数量,选择一批新的脑胶质瘤患者样本28例和冠心病患者样本27例,分别采集血清后,用Protein G通过亲和层析柱进行亲和纯化,获得血清中的IgG复合物。
使用抗Protein S100-A8的特异性抗体,对上述获得的IgG复合物进行免疫结合实验,结果参见图18,Protein S100-A8在脑胶质瘤组中出现更高频率的表达,与冠心病组差异明显,进一步验证了Protein S100-A8可以作为脑胶质瘤相关标志物,用于辅助诊断脑胶质瘤。
本文中应用了具体个例对发明构思进行了详细阐述,以上实施例的说明只是用于帮助理解本发明的核心思想。应当指出,对于本技术领域的普通技术人员来说,在不脱离该发明构思的前提下,所做的任何显而易见的修改、等同替换或其他改进,均应包含在本发明的保护范围之内。
Claims (5)
1.α-2-HS糖蛋白、GTP结合蛋白Di-Ras2和14-3-3sigma作为潜在标志物在制备冠心病诊断或治疗药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述标志物还包括α-2巨球蛋白、纤维蛋白原γ链、纤维蛋白原α链、细胞外基质Gla蛋白、维生素D结合蛋白、凝血因子11、载脂蛋白C-II、载脂蛋白C-III中的至少一种。
3.根据权利要求1或2所述的应用,其特征在于,所述标志物由以下方法获得:
(1)使用能够结合Ig的物质,分别从第一批每个健康样本血清和每个患病样本血清中纯化出Ig复合物;
(2)对Ig复合物进行质谱分析和/或糖谱分析,比较健康样本与患病样本的分析结果,找到只在患病样本的Ig复合物中高频出现或缺失的与Ig相结合的差异蛋白,和/或只在患病样本的Ig复合物中高频出现或缺失的差异糖基,该差异蛋白和/或差异糖基即为疾病相关的潜在标志物;
(3)进一步扩大健康样本和患病样本的数量,采用与步骤(1)相同的方法纯化获得Ig复合物,然后进行以下操作:
针对差异蛋白,利用该差异蛋白的特异性抗体,识别本步骤获得的Ig复合物中的差异蛋白,如果患病样品中该差异蛋白仍然高频出现或缺失,则进一步验证该差异蛋白为疾病相关的潜在标志物;
针对差异糖基,利用该糖基的结合物,或者糖谱分析,识别本步骤获得的Ig复合物的差异糖基,如果患病样本中该差异糖基仍然高频出现或缺失,则进一步验证该差异糖基为疾病相关的潜在标志物。
4.根据权利要求3所述的应用,其特征在于,所述的能够结合Ig的物质,包括ProteinG、ProteinA、Jacalin、Hitrap、抗人IgD、抗人IgE中的至少一种。
5.根据权利要求3所述的应用,其特征在于,所述Ig复合物,包括IgG复合物、IgA复合物、IgM复合物、IgD复合物和IgE复合物中的至少一种。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111329614.0A CN113777330B (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
CN202210415007.4A CN115097137A (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111329614.0A CN113777330B (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210415007.4A Division CN115097137A (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113777330A CN113777330A (zh) | 2021-12-10 |
CN113777330B true CN113777330B (zh) | 2022-05-20 |
Family
ID=78957074
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111329614.0A Active CN113777330B (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
CN202210415007.4A Pending CN115097137A (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210415007.4A Pending CN115097137A (zh) | 2021-11-11 | 2021-11-11 | 一种疾病相关标志物的筛选方法、应用及试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN113777330B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115097147B (zh) * | 2022-08-23 | 2022-11-25 | 细胞生态海河实验室 | 预测奥密克戎复阳风险的生物标志物及代谢、蛋白、联合模型 |
CN117607462B (zh) * | 2024-01-19 | 2024-04-05 | 天津医科大学眼科医院 | 生物标志物在制备诊断后巩膜炎的产品中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014193999A2 (en) * | 2013-05-28 | 2014-12-04 | Caris Science, Inc. | Biomarker methods and compositions |
EP3216861A1 (en) * | 2016-03-11 | 2017-09-13 | Fropharm GmbH | Immunoregulatory cells and methods for their production |
US20210140977A1 (en) * | 2018-04-16 | 2021-05-13 | University Of Cape Town | A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis |
WO2021219009A1 (zh) * | 2020-04-29 | 2021-11-04 | 上海科技大学 | Piwi和/或nmd复合体蛋白在高表达piwi的癌症中的诊断与治疗 |
CN113176411B (zh) * | 2021-03-10 | 2023-12-26 | 北京大学口腔医学院 | 利用唾液检测新型冠状病毒感染的生物标志物及其应用 |
-
2021
- 2021-11-11 CN CN202111329614.0A patent/CN113777330B/zh active Active
- 2021-11-11 CN CN202210415007.4A patent/CN115097137A/zh active Pending
Non-Patent Citations (1)
Title |
---|
Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies;Frank M. Sacks等;《Arteriosclerosis, Thrombosis, and Vascular Biology》;20201130;第40卷;第2714-2727页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113777330A (zh) | 2021-12-10 |
CN115097137A (zh) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113777330B (zh) | 一种疾病相关标志物的筛选方法、应用及试剂盒 | |
Zhan et al. | Mass spectrometry analysis of human tear fluid biomarkers specific for ocular and systemic diseases in the context of 3P medicine | |
US8911960B2 (en) | Method for identifying idiopathic pneumonia progression by measuring the level of mannose-binding protein C | |
EP3260866B1 (en) | Novel biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers | |
Pelaia et al. | Application of proteomics and peptidomics to COPD | |
Laila et al. | Role of proteomics in the discovery of autism biomarkers | |
EP2444814B1 (en) | Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders | |
Iadarola et al. | Recent applications of CE‐and HPLC‐MS in the analysis of human fluids | |
CN110546505A (zh) | 利用代谢组分析诊断白塞氏病的方法 | |
ES2535971T3 (es) | Nuevos biomarcadores para la enfermedad de hígado graso no alcohólico y métodos para detectar la enfermedad de hígado graso no alcohólico que emplean dichos biomarcadores | |
JP2011232164A (ja) | 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法 | |
Fumagalli et al. | Proteomic analysis of exhaled breath condensate from single patients with pulmonary emphysema associated to α1-antitrypsin deficiency | |
RU2406092C2 (ru) | Способ диагностики заболеваний печени | |
US20120135542A1 (en) | Methods and materials for diagnosing light chain amyloidosis | |
Martín et al. | Proteomics as a new tool in forensic sciences | |
BR102014004679B1 (pt) | método preditivo para diagnóstico diferencial de meningites in vitro, uso de proteínas biomarcadoras, e, kit para diagnóstico diferencial de meningites para determinar se um indivíduo possui meningites bacterianas ou meningites virais | |
CN107356761B (zh) | 接骨木凝集素及结合珠蛋白相关蛋白的用途 | |
US20230168256A1 (en) | Methods for using protein biomarkers in idiopathic pulmonary fibrosis | |
CN109061184A (zh) | 一种蒿属植物花粉过敏原组合、应用及试剂盒 | |
Taraskin et al. | Multiplex analysis of inflammation factors in serum using the MALDI-TOF mass spectrometry method | |
Dobrokhotov et al. | Study of the urine proteome in healthy humans | |
CN116298233A (zh) | 用于诊断双相障碍的生物标记物 | |
POACHANUKOON et al. | Shotgun proteomic analysis of saliva identifies potential biomarkers for asthma | |
Tadros | Proteomics may help unleash the mystery of severe COVID-19: A mini review. | |
CN117054536A (zh) | 鉴定或辅助经鉴定成人重症社区获得性肺炎患者的装置和计算机可读存储介质 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240331 Address after: Room 706, No. 16 Chuangyan Street, Kexin Industrial Park, Huangpu District, Guangzhou City, Guangdong Province, 510555 Patentee after: Guangzhou Aisaiji Biomedical Technology Co.,Ltd. Country or region after: China Address before: 100871 No. 5, the Summer Palace Road, Beijing, Haidian District Patentee before: Peking University Country or region before: China |